Sylvester Comprehensive Cancer Center

Company

Related News

Oncology Innovations: ENVISION Trial Results, AI Integration, and Real-Time Symptom Monitoring

Mar 29, 2026

The phase 3 ENVISION trial shows 80% complete response rate for novel bladder cancer chemoablative therapy. AI integration accelerates precision oncology through biomarker identification and targeted treatments. OncoPRO real-time symptom monitoring system enhances patient safety and clinical trial data capture.

Sylvester Cancer Center Launches OncoPRO Real-Time Symptom Monitoring Program

Feb 18, 2026

Sylvester Comprehensive Cancer Center has developed OncoPRO, a next-generation symptom monitoring program that embeds patient-reported outcomes directly into electronic medical records to detect problems earlier and strengthen patient safety in cancer care.